Literature DB >> 22718576

Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.

Gergely Toldi1, Gabriella Bekő, Gabriella Kádár, Emília Mácsai, László Kovács, Barna Vásárhelyi, Attila Balog.   

Abstract

BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the assessment of systemic inflammation. We aimed to evaluate suPAR for the assessment of inflammatory activity in rheumatoid arthritis (RA) patients in remission.
METHODS: In our cross-sectional study we measured plasma suPAR and C-reactive protein (CRP) levels as well as erythrocyte sedimentation rate (ESR) in 120 RA patients at various stages of disease activity and 29 healthy age-matched controls.
RESULTS: suPAR, CRP and ESR values were higher in RA patients compared to healthy individuals. When suPAR levels were analyzed according to DAS28 scores of RA patients, suPAR level in the subgroup with DAS28≤2.6 was lower than in the subgroup with DAS28>2.6, but still higher than in controls [4.45 (3.33-5.56) ng/mL vs. 3.66 (3.10-4.67) ng/mL vs. 2.80 (2.06-3.42) ng/mL, p<0.0001, median (interquartile range)]. In contrast, CRP and ESR values were comparable in the subgroup with DAS28≤2.6 and in healthy individuals. We further analyzed the correlation between the number of tender and/or swollen joints and suPAR levels in RA patients in remission. suPAR values were significantly higher in patients with four tender and/or swollen joints than in patients with 2-3 or 0-1 tender and/or swollen joints.
CONCLUSIONS: While CRP and ESR values indicate remission of the chronic inflammatory process in RA, suPAR values are still elevated compared to healthy individuals. suPAR might be particularly valuable in the recognition of inflammatory activity in patients who are in remission according to DAS28 scores but have symptoms of tender and/or swollen joints.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22718576     DOI: 10.1515/cclm-2012-0221

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  14 in total

Review 1.  Focal segmental glomerular sclerosis: do not overlook the role of immune response.

Authors:  Francesco Reggiani; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-02-20       Impact factor: 3.902

2.  Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.

Authors:  Hong Guo; Lan-Xia Zhou; Haizhen Ma; Bei Liu; Juan Cheng; Yun-Yun Ma; Li Zhao
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

3.  Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?

Authors:  Fabrizio Scotti; Paolo Milani; Marco Setaccioli; Silvia Maestroni; Nicolai Sidenius; Valentina De Lorenzi; Amedeo Massacesi; Fulvio Bergamini; Gianpaolo Zerbini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-07       Impact factor: 3.117

4.  Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.

Authors:  Özlem Akdoğan; Ayşegül Atak Yücel; Zeynep Gök Sargin; Cemile Sönmez; Güldal Esendağli Yilmaz; Seren Özenirler
Journal:  J Clin Exp Hepatol       Date:  2018-02-16

Review 5.  Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.

Authors:  Wentao Ni; Yuliang Han; Jin Zhao; Junchang Cui; Kai Wang; Rui Wang; Youning Liu
Journal:  Sci Rep       Date:  2016-12-19       Impact factor: 4.379

6.  The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.

Authors:  Fei Huang; Yueqiang Li; Ranran Xu; Anying Cheng; Yongman Lv; Qingquan Liu
Journal:  Mediators Inflamm       Date:  2020-04-07       Impact factor: 4.711

7.  Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study.

Authors:  Anne Langkilde; Janne Petersen; Henrik Hedegaard Klausen; Jens Henrik Henriksen; Jesper Eugen-Olsen; Ove Andersen
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

8.  Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy.

Authors:  István Ivancsó; Gergely Toldi; Anikó Bohács; Noémi Eszes; Veronika Müller; János Rigó; Barna Vásárhelyi; György Losonczy; Lilla Tamási
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

9.  The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders.

Authors:  Barna Vasarhelyi; Gergely Toldi; Attila Balog
Journal:  EJIFCC       Date:  2016-04-20

10.  A New Explanation of Inflammation in Rheumatoid Arthritis Patients With Respect to Claudin-5, Matrix Metalloproteinase-9, and Neuroserpin.

Authors:  Sevil Arabacı Tamer; Gönül Gürol; İbrahim Tekeoğlu; Halil Harman; İhsan Hakkı Çiftçi
Journal:  Arch Rheumatol       Date:  2016-08-01       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.